Anemia, Sickle Cell
NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease
Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval
Editas Medicine Undergoes Major Restructuring, Laying Off 65% of Staff Including CMO Amid Failed Search for RENI-CEL Partner
Editas Medicine, layoffs, gene editing, biotech, RENI-CEL, sickle cell disease, thalassaemia, CMO, workforce reduction, restructuring.
Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment
Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement
Vertex’s CASGEVY Marks Historic Milestone with First Commercial Patient Infusions, Paving the Way for 2025 Launches
CASGEVY, Vertex Pharmaceuticals, gene therapy, sickle cell disease, beta thalassemia, CRISPR/Cas9, FDA approval, commercial patient infusions, 2025 launches.
Beam Therapeutics Reports Promising Early Results in Sickle Cell Disease Base Editing Therapy, Despite Conditioning-Related Fatality
Beam Therapeutics, Sickle Cell Disease, Base Editing, Gene Therapy, BEAM-101, ESCAPE, Conditioning, Patient Death
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns
Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events
Bluebird’s Struggles with Sickle Cell Gene Therapy Launch Impact Financial Stability
Bluebird Bio, sickle cell disease, gene therapy, Lyfgenia, loan rework, cash runway, financial stability
Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment
Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies